Safety and tolerability of B1344 injections for NAFLD
Part of Digestive system clinical trials.
This trial tests whether multiple injections of B1344 are safe and tolerable in people with nonalcoholic fatty liver disease (NAFLD). It aims to find the right dose and check how the drug works in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and Chinese
- You have NAFLD with a liver fat level of at least 10% on an MRI scan
- You have at least one metabolic risk factor like being overweight, having high blood sugar, high blood pressure, or abnormal blood fats
- Your weight has been stable (no more than 5% change) in the last 6 weeks
- You agree to use effective birth control during the trial and for 3 months after
- You do not have cirrhosis, other liver diseases, or certain other serious health conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HP515 for people with non-alcoholic fatty liver disease, including NASH or MASH. It aims to see if the drug can help reduce liver fat and improve liver health.
This study tests an experimental drug called SNP-610 for a liver condition called NASH (fatty liver with inflammation). The goal is to see if the drug helps improve liver health compared to a placebo.
This study collects health information from people with non-alcoholic fatty liver disease (NAFLD), a condition where fat builds up in the liver. It aims to learn more about the disease to improve future care.
This trial tests two new injections (HRS-4729 and HRS-9531) for people with MASH, a type of fatty liver disease. The study aims to see if these drugs can help reduce liver fat and improve liver health.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
This study tests a new injected drug (TQA2225/AP025) that may help reduce liver fat and inflammation in people with NASH (a type of fatty liver disease with scarring). It’s for adults who have had a recent liver biopsy and MRI confirming NASH and moderate liver fat.
Hear when a new NASH - Nonalcoholic Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.